Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Pluvicto™ continues strong start in the US
1
GROWTH
PLUVICTO™
Rapid launch uptake in US
Q3 sales of USD 80m; NBRx share 14%
in post-taxane mCRPC
Over 120 centers actively ordering; focus in Q3
on smooth supply and customer service
More than 75% of insured lives covered
(across Medicare, Medicaid and private payers)
Permanent A code effective in October
Preparing for further expansion
✓ Steadily expanding treatment centers in the US
✓ Significantly increasing manufacturing capacity
(Ivrea in 2022; Millburn and Indianapolis planned in 2023)
Positive CHMP opinion²; expected EU rollout 2023
✓ Earlier line studies on track:
■
PSMAfore (pre-taxane) readout expected YE 20221
■ PSMAddition (mHSPC) readout expected 2024
CHMP Committee for Human Medicinal Products
NBRX - New to Brand prescriptions mCRPC metastatic castration-resistant prostate cancer
13 Investor Relations | Q3 2022 Results
1. Event-driven, could move to early 2023. 2. Oct 2022.
✓ NOVARTIS | Reimagining MedicineView entire presentation